Science beakers in a line depicting cancer research

‘High-risk’ cancer research given £2m funding boost

Four clinical research teams across the UK have been awarded an equal share of £2m to test innovative ways of tackling hard-to-treat cancer, the secretary of state for science, Michelle Donelan, has announced.

Included in the funding is a project that will evaluate how AI can be used to read lung scans and more precisely predict cancer resistance.

The data gathered from the programme will inform the development of drugs that target resistant cancer cells. King’s College London’s Tim Witney will lead on this.

Another £500,000 will go to researchers led by Lauren Ford at Imperial College London who will investigate how lasers can be used to remove brain cancer cells.

This technique could reduce the collateral damage caused to other cells and provide real-time data on the nature of the cancer, which can be used to improve post-operative care.

In another initiative, experts at Cardiff University and Brain Tumour Research will explore the potential of ‘cryogel’ to help deliver drugs directly to brain tumours.

In theory, this can overcome the blood-brain barrier and reduce the knock-on effect to non-cancerous brain cells. The project will be led by Ben Newland.

The fourth round of investment will be used to try and optimise engineered nanoparticle therapeutics for oesophageal cancer. Researchers hope to target cells that inhibit the efficacy of medicines.

This work will be conducted by researchers from The University of Manchester and The Christie NHS Foundation Trust – Sara Valpione will lead.

Science, innovation and technology secretary, Michelle Donelan, said: “By investing in high-risk but high-reward techniques – including artificial intelligence – we are backing our ambitious, world class researchers to build on generations of discoveries and give more people a fighting chance to live long and healthy lives.”

Health secretary, Steve Barclay, added: “We are looking at how new technology can help provide the best possible treatments for patients and this £2 million investment will be vital in supporting researchers to understand and treat those cancers with lower survival rates.”

Image credit: iStock

NHE September/October 2023

NHE September/October 2023

Empowering the next generation to lead the way in hard-to-treat cancers.

The September/October 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep. 36
How interoperability can support the NHS's core goals
with Ed Platt

In episode 36 of the National Health Executive podcast, we were joined by Omnicell’s UK professional services director, Ed Platt, to discuss interoperability in the NHS, practical examples of where it can be leveraged best, the importance of the health service's digital transformation journey and more.

More articles...

View all